{"id":"cb03-154","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Vomiting"}]},"_chembl":{"chemblId":"CHEMBL3663457","moleculeType":"Small molecule","molecularWeight":"422.46"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting SGLT2, CB03-154 reduces glucose reabsorption in the kidneys, thereby lowering blood glucose levels. This makes it a potential treatment for type 2 diabetes.","oneSentence":"CB03-154 is a small molecule that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:50:06.080Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT07238868","phase":"PHASE2","title":"An Open-label Study to Evaluate Safety, Tolerability, and Efficacy of CB03-154 in Subjects Diagnosed With Epilepsy","status":"RECRUITING","sponsor":"Shanghai Zhimeng Biopharma, Inc.","startDate":"2025-08-14","conditions":"Focal Epilepsy","enrollment":144},{"nctId":"NCT07082192","phase":"PHASE2, PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Different Doses of CB03-154 in Adult Patients With Amyotrophic Lateral Sclerosis (ALS)","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Zhimeng Biopharma, Inc.","startDate":"2025-09-29","conditions":"ALS (Amyotrophic Lateral Sclerosis)","enrollment":240},{"nctId":"NCT06612775","phase":"PHASE2","title":"A Study to Evaluate the Safety, Tolerability, and Efficacy of CB03-154 in Adult Patients With Focal Epilepsy","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Zhimeng Biopharma, Inc.","startDate":"2024-09","conditions":"Focal Epilepsy","enrollment":180},{"nctId":"NCT05502549","phase":"PHASE1","title":"A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CB03-154 in Healthy Participants in Australia","status":"COMPLETED","sponsor":"Shanghai Zhimeng Biopharma, Inc.","startDate":"2022-11-29","conditions":"Healthy Volunteers","enrollment":56},{"nctId":"NCT05499260","phase":"PHASE1","title":"A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CB03-154 in Healthy Participants","status":"UNKNOWN","sponsor":"Shanghai Zhimeng Biopharma, Inc.","startDate":"2022-05-02","conditions":"Healthy Volunteers","enrollment":70}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"CB03-154","genericName":"CB03-154","companyName":"Shanghai Zhimeng Biopharma, Inc.","companyId":"shanghai-zhimeng-biopharma-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CB03-154 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}